First-quarter revenue reached $4.35 billion, surpassing analyst estimates, with U.S. net earned premiums up 3.5% to $1.56 billion and Japan premiums down 6.4% to $1.57 billion.
Adjusted earnings per share were $1.75, slightly below the $1.79 expected by analysts. U.S. adjusted revenue grew 3.4%, while Japan's fell 4.4%.
CEO Daniel Amos credited new business in medical, cancer, and life insurance in Japan, and group benefits in the U.S., for the growth. The results highlight Aflac's ongoing geographic diversification.
With Japan revenue falling, can a new $550B US-Japan deal fuel Aflac's future growth?
Beyond investment gains, why did Aflac's adjusted earnings fail to meet Wall Street's expectations?
How will Japan's new regulations reshape Aflac's strategy in its largest international market?
As healthcare costs soar, what is Aflac's next move in the employee benefits market?
Aflac's stock is called 36% undervalued. What is the market failing to see?
Is Aflac's 'human-first AI' a buzzword, or a real competitive advantage in insurance?